Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats
Tóm tắt
Recent research has suggested that cognitive disorders are a persistent trait of mental illnesses such as schizophrenia. Cognitive deficits in the course of schizophrenia may be due to the disease and/or drug therapy, especially with old-generation drugs. Several clinical experiments have indicated the beneficial effects of new-generation antipsychotics on cognitive processes in patients treated for mental disorders. Aripiprazole is a new, atypical antipsychotic with a unique mechanism of action, which may have positive effects on cognitive functions. The aim of this study was to investigate the effects of aripiprazole on spatial memory in the Morris water maze and antidepressant activity in the Porsolt test. In addition, we examined whether aripiprazole had any side effects in the chimney test. The behavioral tests showed that aripiprazole improved spatial memory in rats and had antidepressant and anxiolytic effects after a single treatment; however, aripiprazole impaired motor coordination after repeated administration. We concluded that aripiprazole could be an effective antipsychotic for the treatment of patients with schizophrenia or bipolar disorder who have associated anxiety and cognitive deficits.
Tài liệu tham khảo
Abilify (Aripiprazole) - Drug Interactions, Contraindications, Overdosage. www.DrugLib.comlk. 2010.06.10.
Ballard M, Basso A, Gallagher K, Browman K, Fox G, Drescher KU, Gross G, Decker MW: The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment. Psy-chopharmacology, 2007, 190, 1–11.
Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski F, Norman T: Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl, 2007, 434, 41–49.
Blin OA: Comparative review of new antipsychotics. Can J Psychiatry, 1999, 44, 235–244.
Boisser JR, Tardy J, Diverres J: Anew simple methods to explore the action - chimney test (French). Med Exp, 1960, 3, 81–84.
Bourin M, Chenu F, Prica C, Hascoët M: Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychophar-macology, 2009, 206, 97–107.
Bowles TM, Levin GM: Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother, 2003, 37, 687–694.
Colonna L, Petit M, Lepine JP: Bromocriptine in affective disorders. A pilot study. J Affect Disord, 1979, 1, 173–177.
Cornblatt B, Kern RS, Carson WH, Dunbar GC, Ali M, Ingenito G, Green MF.: An open-label comparison of the neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. VIIIth International Congress on Schizophrenia Research, Whistler, 2002.
Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, Cichocki M.: Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and corticalconcentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep, 2009, 61, 1017–1023
Dailly E, Chenu F, Renard CE, Bourin M: Dopamine, depression and antidepressants. Fundam Clin Pharmacol, 2004, 18, 601–60.
Dias R, Robbins TW, Roberts AC: Dissociation in prefrontal cortex of affective and attentional shifts. Nature, 1996, 380, 69–72.
Dias R, Robbins TW, Roberts AC: Primate analogue of the Wisconsin card sorting test: Effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci, 1996, 110, 872–886.
Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F: Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci, 2005, 25, 10831–10843.
Egashira N, Okuno R, Matsushita M, Abe M, Mishima K, Iwasaki K, Nishimura R et al.: Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Eur J Pharmacol, 2008, 592, 103–108.
Feltenstein MW, Altar CA, See RE: Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry, 2007, 61, 582–590.
Gelder MG, López Ibor JJ, Andreasen NC: New Oxford Textbook of Psychiatry. Oxford University Press, Oxford, 2000.
Grace AA: The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl, 1992, 36, 91–131.
Greenaway M, Elbe D: Focus on Aripiprazole: Areview of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry, 2009, 18, 250–260.
Ichimaru, Y, Egawa T, Sawa A: 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol, 1995, 68, 65–70.
Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R: The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neu-ropsychopharmacol, 2000, 10, 223–328.
Kinghorn WA, McEvoy JP: Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother, 2005, 5, 297–307.
Levoyer D, Drapier D, Fadier-Salice G, Millet B: Clinical impact of aripiprazole in patients suffering from schizophrenia. Encephale, 2007, 33, 332–338.
Li Z, Ichikawa J, Dai J, Meltzer HY: Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol, 2004, 493, 75–83.
Kamei J, Miyata S, Sunohara T: Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci, 2008, 108, 381–384.
Konradi C, Heckers S. Antipsychotic drugs and neuro-plasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry, 2001, 50, 729–742.
Maj J, Rogóż Z: Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol, 1999, 51, 471–475.
McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ: Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother, 2007, 8, 1001–1009.
McKenna P, Clare L, Baddeley AD: Schizophrenia. In: Handbook of Memory Disorders. Ed. Baddeley AD, John Wiley & Sons, New York, 1995, 271–292.
Morris R: Development of a water-maze procedure for studying spatial learning in a rat. J Neurosci Methods, 1984, 11, 47–60.
Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T: Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology, 2009, 202, 315–328.
Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S: Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology, 2006, 31, 1854–1863.
Nordquist R, Risterucci C, Moreau J, Von Kienlin M, Kunnecke B, Maco M, Freichel C et al.: Effects of aripi-prazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology, 2008, 54, 405–416.
Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379–391.
Renard CE, Dailly E, David DJ, Hascoët M, Bourin M: Neurochemical changes following the mouse forced swimming test but not the tail suspension test. Int J Neu-ropsychopharmacol, 2003, 17, 449–455.
Renard CE, Dailly E, Nic Dhonnchadha BA, Hascoët M, Bourin M: Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog Neuropsychopharmacol Biol Psychiatry 2004, 28, 1255–1259.
Renard CE, Fiocco AJ, Clenet F, Hascoët M, Bourin M: Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology, 2001, 159, 42–50.
Rossetti ZL, Lai M, Hmaidan Y, Gessa GL: Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine. Eur J Pharmacol, 1993, 242, 313–315.
Sams-Dodd F: Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol, 1996, 7, 3–23.
Sawaguchi T, Goldman-Rakic PS: D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science, 1991, 251, 947–950.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28, 1400–1411.
Shopsin B, Gershon S: Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495). Neuropsychobiology, 1978, 4, 1–14.
Snigdha S, Neill J: Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behav Brain Res, 2008, 191, 26–31.
Snigdha S, Neill JC: Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - a preliminary investigation. Behav Brain Res, 2008, 187, 489–94.
Stip E, Tourjman V: Aripiprazole in schizophrenia and schizoaffective disorder: Areview. Clin Ther, 2010, 32, Suppl 1, 3–20.
Tan HY, Callicott JH, Weinberger DR: Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex, 2007, 17, 171–181.
Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S: Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry, 2001, 7, 317–321.
Urban JD, Vargas GA, Zastrow MV, Mailman RB: Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacology, 2007, 32, 67–77.
Waknine Y: FDA Approvals: Remicade, Abilify, Langsten Catheter, and Others. Medscape Medical News, 2004.
Wędzony K, Fijał K, Maćkowiak M, Chocyk A: Detrimental effect of postnatal blockade of N-methyl-D-aspartate receptors on sensorimotor gating is reversed by neuroleptic drugs. Pharmacol Rep, 2008, 60, 856–864.
Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M et al.: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol, 2006, 546, 88–94.
www.drugs.com/ppa/aripiprazole.html, 03.06.2009, 19:50.
Zhang J, Kowal D, Nawoschik S, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol, 2006, 71, 521–529.
Zocchi A, Fabbri D, Heidbreder CA: Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontalcortex. Clin Psychophar-macol and Neurosci, 2005, 387, 3, 157–161.